GlobeNewswire PharmaOriginal article
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
Phase 2positiveTEV-408Positive
AI Analysis
Summary
Teva announced positive Phase 2a topline results for TEV-408, an anti-IL-15 antibody candidate, demonstrating significant prevention of gluten-induced intestinal damage in celiac disease patients, supporting the company's pipeline-in-a-product strategy.
Clinical Trial Data
Phase
2a
Primary Endpoint
Met
Outcome Details
Significant prevention of gluten-induced intestinal damage
Importance:7/10
Sentiment:
0.80
anti-IL-15 antibodyceliac diseasepositive datapipeline validation
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 2, 2026 11:03 AM